Singapore, Sept. 16 -- Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

Designed to expand and augment the company's portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for development of gene therapies.

HEK293 cells are well established for gene therapy applications in upstream bioprocessing, offering reliable growth rates, high transfection success and expression of cellular factors needed for virus replication. BalanCD HEK293 Perfusion A furth...